Search Results

You are looking at 21 - 30 of 248 items for :

  • "type 1 diabetes" x
  • All content x
Clear All
Free access

Shiying Shao, Yun Gao, Bing Xie, Fei Xie, Sai Kiang Lim, and GuoDong Li

Introduction Islet or pancreas transplantation is a promising approach to treat type 1 diabetes ( Shapiro et al . 2000 , Halban 2004 , Vaithilingam et al . 2008 , Ichii & Ricordi 2009 ). However, the limited supply of cadaveric pancreata and

Free access

Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, and Thomas Klein

. Annual Review of Immunology 23 447 – 485 . doi:10.1146/annurev.immunol.23.021704.115643 . Atkinson MA Eisenbarth GS 2001 Type 1 diabetes: new perspectives on disease pathogenesis and treatment . Lancet 358 221 – 229 . doi:10.1016/S0140

Free access

Maristela Mitiko Okamoto, Gabriel Forato Anhê, Robinson Sabino-Silva, Milano Felipe dos Santos Ferreira Marques, Helayne Soares Freitas, Rosana Cristina Tieko Mori, Karla Fabiana S Melo, and Ubiratan Fabres Machado

resistance is involved in the pathogenesis of type 2 diabetes mellitus (T2DM; Björnholm & Zierath 2005 ). In type 1 diabetes mellitus (T1DM), apart from its well-known pathogenesis, insulin resistance has also been described in both undertreated

Free access

Lorraine O’Driscoll, Patrick Gammell, Eadaoin McKiernan, Eoin Ryan, Per Bendix Jeppesen, Sweta Rani, and Martin Clynes

Introduction Cell replacement therapies are potential alternatives to the insulin injections presently employed to control blood glucose in type 1 diabetes. Indeed, it has been demonstrated that this condition may be cured (at least

Free access

S K Richards, L E Parton, I Leclerc, G A Rutter, and R M Smith

Introduction In the wake of improvements achieved by Shapiro et al. (2000) , human islet transplantation is now considered a potentially useful treatment modality for type 1 diabetes ( Korsgren et al. 2005 ). At present, however

Free access

Haiyong Chen, Hui-Yao Lan, Dimitrios H Roukos, and William C Cho

2013 ). DM is a complex disease characterized by high blood glucose levels. There are two major forms of diabetes. Type 1 diabetes (T1D) results from a lack of insulin production in pancreatic β-cells. T2D is due to resistance to insulin, resulting in

Free access

Gabriele Wolf, Nicole Aumann, Marta Michalska, Antje Bast, Jürgen Sonnemann, James F Beck, Uwe Lendeckel, Philip Newsholme, and Reinhard Walther

Introduction Autoimmune destruction of pancreatic β cells during the development of type 1 diabetes is a complex process involving both cellular and humoral elements of cytotoxicity ( Mandrup-Poulsen et al . 1990 ). It is characterized by insulitis

Free access

Sheng-Gao Tang, Xiao-Yu Liu, Ji-Ming Ye, Ting-Ting Hu, Ying-Ying Yang, Ting Han, and Wen Tan

mechanisms. The present study evaluated: (1) whether STVNa could ameliorate or inhibit the development and progression of type 1 diabetes-induced cardiac dysfunction; (2) whether the potential effect of STVNa was related to anti-hyperglycemia and/or AGE

Free access

Spyridon Champeris Tsaniras and Peter M Jones

maintain whole-body glucose homeostasis, at which point the patient presents with the clinical symptoms of type 1 diabetes. In brief, reduced circulating insulin causes decreased cellular uptake of glucose by peripheral tissues as well as hepatic

Free access

Abdullah Cim, Greta J Sawyer, Xiaohong Zhang, Haibin Su, Louise Collins, Peter Jones, Michael Antoniou, Jean-Paul Reynes, Hans-Joachim Lipps, and John W Fabre

Introduction The introduction of insulin therapy for type 1 diabetes in the 1920s represented a monumental advance ( Banting et al . 1922 ). However, in spite of increasingly sophisticated approaches to regulating blood glucose with exogenous